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Objective: The use of benzodiazepines (BDZs) represents a critical issue since a long-term treatment may lead to dependence. This study
aimed at evaluating socio-demographic and clinical characteristics of BZD long-term users who followed a detoxification program at a
tertiary care center.
Method: Two hundred-five inpatients were evaluated. Socio-demographic (e.g., gender, age, education) and clinical information (e.g., BZD
used, dose, reason of prescription) was collected. BZDs dose was standardized as diazepam dose equivalents and was compared via the
Defined Daily Dose (DDD). Chi-square, Fisher test, ANOVA and Bonferroni analyses were performed.
Results: Females were more frequently BDZ long-term users than males. Hypnotic BZDs were frequently prescribed for problems different
from sleep disturbances. Lorazepam, alprazolam, and lormetazepam were the most prescribed drugs. Lorazepam was more frequently used by
males, consumed for a long period, in pills, and prescribed for anxiety. Lormetazepam was more frequently consumed by females with a high
school education, having a psychiatric disorder, taken in drops and prescribed for insomnia. Lormetazepam had the highest DDD.
Conclusion: A specific profile of BZD long-term user seems to exist and presents different socio-demographic and clinical characteristics
according to the benzodiazepine taken into account.
© 2016 Elsevier Inc. All rights reserved.1. Introduction
For decades, benzodiazepines (BZDs) have been recom-
mended as the standard treatment of anxiety and insomnia
[1–4]. In late 1990s, the most frequent recommendation for
the treatment of anxiety disorders changed to a selective
serotonin reuptake inhibitor (SSRI) or to a serotonin
norepinephrine reuptake inhibitor (SNRI) [5] and BDZs
were replaced by newer antidepressants mainly due to the
claimed BZD withdrawal, rebound, overuse, and abuse [6].
However, the new SSRI and SNRI classification of
withdrawal syndromes, which includes persistent postwith-
drawal disorders [7], suggested that newer antidepressants
have similar problems of withdrawal and rebound as BZDs.
In addition, the literature has provided evidence for a
reappraisal of BZDs as first-line pharmacological treatment
of anxiety disorders without depression; and major differ-Declaration of interest: No conflict of interests.
⁎ Corresponding author. Tel.: +39 0552755066; fax: +39 0556236047.
E-mail address: fiammetta.cosci@unifi.it (F. Cosci).
http://dx.doi.org/10.1016/j.comppsych.2016.06.008
0010-440X/© 2016 Elsevier Inc. All rights reserved.ences in terms of rebound syndrome, potency, risk of abuse,
and pharmacokinetics have been shown among BZDs [6].
Analyses of possible predictors for BZD long-term use
show that gender is of minor importance [8,9] although more
women use than men and the long-term use is much more
common among women than men [9,10]. Older age was
found to be an important predictor [8–11] as well as previous
use [8,9] and low level of education [12]. Patients who
obtained BDZ prescriptions from doctors in hospital care and
patients who obtained prescriptions from doctors working in
different settings continued to use BZDs to a greater extent
than those who received prescriptions from private practi-
tioners or health centers doctors alone [9]. Also a combined
use of hypnotics together with anxiolytics seems to be a
significant factor in frequent or daily use [9]. Alcohol
consumption, anxiety and tension have been positively
related to long-term use, while exercise seems negatively
related to it [13]. In addition, according to a recent survey,
BZD hypnotics have been associated with increased risk of
high-dose use among long-term users, compared to diaze-
pam; BZD anxiolytics were associated with significantly
212 F. Cosci et al. / Comprehensive Psychiatry 69 (2016) 211–215lower risk of high-dose use, the lowest risk being with
clobazam and clonazepam; finally, triazolobenzodiazepines
(i.e., alprazolam and triazolam) were at risk for high-dose use
among continuous users [11]. Thus, not all benzodiazepines
seemed to be the same [14].
In this framework, we assessed socio-demographic and
clinical characteristics of BZD long-term users who referred
to a tertiary care center for detoxification with the aim to
verify whether routine data are consistent with the results
provided by population surveys.2. Methods
2.1. Sample and procedure
BZD dependent patients who consecutively referred to
the Addiction Unit (AU) of the Verona University Hospital
(Verona, Italy) between January 2003 and December 2014
were evaluated. Exclusion criteria were: lifetime and current
substance use disorders, other than nicotine and benzodiaz-
epines; addiction to more than one BZD (cases with more
than one BZD long-term use were excluded to prevent
interpretive bias and allow a clear identification of a
socio-demographic and clinical profile of the long-term
users for each benzodiazepine).
Inclusion criteria were: age older than 18 years;
diagnosis of BZD dependence according to the DSM-IV
criteria [15]; BZD addiction lasting from at least 180 days
[16]. Eligible patients provided written informed consent
and were evaluated by the medical doctors of the AU via
standardized questions already used in the past [17,18]
which allowed to collect the following information: demo-
graphic characteristics; reasons for BDZ prescription; average
daily BZD dose consumed in the last 180 days; duration of
BZD use; route of administration; co-occurrent psychiatric
disorder(s). The study protocol fully adhered to guidelines of
the Ethic Committee of the Verona University Hospital,
Verona, Italy.
2.2. Statistical analyses
The different BZDdosewas compared via theDefinedDaily
Dose (i.e., 1 DDD is the therapeutic daily dose established by
WHO for any drug) [19] and BZDs dose was standardized as
diazepam dose equivalents using one of the most accepted
conversion tables where 10 mg of diazepam is equal to: 1 mg of
lorazepam, 2 mg of lormetazepam, 0.25 mg of triazolam, 3 mg
of delorazepam, 0.5 mg of alprazolam [20], 6 mg bromazepam
[11], 1.5 etizolam [21,22], 20 mg temazepam [11,23].
Comparisons were performed using the chi-square test
and Fisher's exact test for dichotomous variables, and the
analysis of variance (ANOVA) plus Bonferroni test as a
post-hoc analysis for continuous variables.
Significance levels were set at p ≤ 0.05 (two-tailed). All
of the analyses were performed using SPSS, version
21.0 [24].3. Results
Two hundred-five subjects were enrolled. Among them
132 were females (64.4%) and 73 males (35.6%), with a
mean age of 46.39 ± 11.33 years. Most subjects had a high
school diploma (n = 76, 37.1%), followed by middle school
diploma (n = 55, 26.8%), university degree (n = 37, 18%),
and primary school education (n = 11, 5.4%). Distribution
of marital status included: 81 (50.93%) married, 76 (47.2%)
unmarried, and 3 (1.86%) widowed. About 54% (n = 110,
55.7%) of the sample was employed, 16.1% (n = 33) was
unemployed, 20.5% (n = 42) was retired or housewife.
Almost the whole sample (93.2%, n = 191) had at least one
psychiatric disorder. The most frequent mental illnesses were
anxiety or depressive disorders (n = 151, 79.47%), followed
by bipolar disorder (n = 17, 8.94%), personality disorders
(n = 12, 6.31%), others (n = 8, 4.21%). The use of BZD
lasted 80.87 ± 79.62 months.
Among anxiolytic BZDs, lorazepam had the highest rate
of use in the total sample, followed by alprazolam. Among
hypnotic BZDs, lormetazepam had the highest rate of use in
the total sample (Table 1).
Lorazepam and delorazepam were more likely to be
consumed by males while lormetazepam was more likely to
be consumed by females (Table 1). No difference was found
in terms of age (Table 2).
When the distribution by working activity, civil status,
and education for each benzodiazepine was evaluated,
statistically significant results were found only for education
(diazepam: 2 subjects completed the primary school, 1
completed the middle school, and 1 the high school, p =
0.01, df = 4; lormetazepam: 6 subjects completed the
primary school, 29 the middle school, 57 the high school,
29 the college, for 3 subjects the information was not
available, p = 0.02, df = 4).
Lorazepam was more likely to be consumed in pills while
lormetazepam was more likely to be consumed in drops
(Table 1). The 5.36% of the prescriptions for anxiolytic
BZDs was for insomnia and the 24.39% of prescriptions for
hypnotic BZDs was for anxiety (98% of prescriptions was
due to lormetazepam).
Lormetazepam was more frequently prescribed in cases
with a diagnosis of at least one psychiatric disorder
than those without psychiatric disorders (n = 13, 92.9% vs
n = 123, 64.4%; p = 0.03).
When the benzodiazepines were compared in terms of
diazepam equivalent dose and duration of use, no statistically
significant results were found. Lorazepam was noted to have
the longest duration of use while lormetazepam had the
highest DDD (Bonferroni post-hoc p b 0.001) (Table 2).4. Discussion
The present study shows that BZD long-term users asking
for detoxification are females in about two thirds of cases,
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213F. Cosci et al. / Comprehensive Psychiatry 69 (2016) 211–215have a high-school level of education in about one third of
cases, are married and employed in about half of cases, and
have a mean age of about 46 years. The majority of subjects
used lorazepam and alprazolam, among anxiolytic BZDs,
and lormetazepam, among hypnotic BZDs. The prescription
of anxiolytic BZDs was for sleep disturbances rather than for
anxiety problems in about 5.36% of the cases, while the
prescription of hypnotics BZDs was for anxiety rather than
for sleep disturbances in about 24.39% of the cases. Among
anxiolytic BZDs, lorazepam was more frequently used by
males, consumed in pills, and used for a longer period. Even
delorazepam was more frequently used by males. Among
hypnotic BZDs, lormetazepam was more frequently used by
females with a high school education, having a psychiatric
disorder, and taken in drops. The highest DDD value was
found for lormetazepam.
The findings on gender distribution are consistent with
population surveys showing that BZDs intake is twice in
women than in men [16,25–29] and with the Luxembourg
national registry study which found significantly more
high-dose long-term users among women than among men
[11]. Interestingly, anxiolytic BZDs were more likely to be
used by men while hypnotics BZDs were mostly consumed
by women. Unfortunately, no data from the literature
evaluated gender distribution among anxiolytic and hypnotic
BZDs, thus comparisons on this issue are not possible.
The present sample seems to have a relatively high level of
education; this result is only apparently not consistent with the
literature [12] since Mant et al. (1988) referred to the general
population while we evaluated tertiary care patients, who
frequently have an intermediate level of education [30–32].
Among anxiolytic BZDs, lorazepam and alprazolam had
the longest-term use while the most hypnotic BZD used was
lormetazepam. These findings are consistent with earlier
population surveys [11,18,28,33,34] and can be related to the
pharmacological characteristics of BZDs which differentiate
their dependence potential. Dependence on BZDs following
continuous use is most notable for those with a medium
elimination half-life such as lorazepam and lormetazepam
[35] or for triazolobenzodiazepines, such as alprazolam,
which are characterized by high level of lipid solubility [6].
The present research also reported a higher rate of
prescriptions, which apparently do not match the indication
(i.e., improper prescription), for hypnotics BZDs than for
anxiolytic BZDs. Although it is widely known that BDZs
may be prescribed improperly, the extent of this problem
remains uncertain [36] since studies aimed at evaluating the
pattern of prescription of BDZs have yielded mixed results.
On one hand, a trend to prescribe anxiolytic BDZs mostly for
anxiety disorder and hypnotic BDZs mostly for insomnia
was shown [37]; on the other hand, some authors found that
both anxiolytics and hypnotics are prescribed for sleep
disorders and/or anxiety disorders [38,39]. It is also
noteworthy that most of these studies [27,34,40,41] assessed
BZDs as a whole rather than estimating the pattern of
prescription of each BDZ.
Table 2
Descriptive (mean ± SD) of continuous variables. Analysis of variance (ANOVA) plus Bonferroni test was applied for age, Defined Daily Dose, diazepam
equivalent dose, and duration of treatment.
Age (years)
N = 203
Dose (mg)
N = 202
Times × Defined Daily
Dose N = 202
Diazepam equivalent dose
N = 201
Duration of use (months)
N = 198
mean SD p mean SD mean SD p mean SD p mean SD p
BZDs anxiolytics
lorazepam 46.87 9.48 29.13 30.71 13.10 16.47 291.29 307.11 118.97 123.49
alprazolam 46.93 9.68 14.27 10.36 14.27 10.36 285.33 207.26 74.93 71.26
bromazepam 43.89 8.58 152.83 258.82 15.29 25.88 305.56 517.73 77.11 60.58
delorazepam 40.50 12.71 15.67 13.58 5.23 4.52 53.33 45.09 55.50 51.23
diazepam 40.25 17.15 0.45 85.00 75.05 8.50 7.51 b0.001 85.00 75.06 0.26 76.50 109.69 0.19
etizolam 37.25 10.21 29.50 24.17 – – – – 44.00 27.71
BZDs hypnotics
lormetazepam 47.05 11.90 65.45 67.66 65.45 67.66 338.35 29.12 75.54 68.15
triazolam 39 – 5 – 20 – 100 – 8 –
temazepam 48.00 – 13.00 – – – 1 – 72.00 –
BZDs: benzodiazepines.
214 F. Cosci et al. / Comprehensive Psychiatry 69 (2016) 211–215Both anxiolytic and hypnotic BZDs seemed to be used
mainly by patients with intermediate education. This finding
can be explained by the fact that the sample under
study mainly included subjects having a medium–high
level of education.
Finally, lormetazepam had a higher DDD than lorazepam.
The result is consistent with the literature [11] and, as already
suggested [18], some features may make lormetazepam
long-term use easier than that of other BDZs (i.e., high
therapeutic index, formulation in drops having a 95%
concentration of alcohol) [18].
Some limitations should be taken into account: (a)
psychiatric diagnoses were formulated without a diagnostic
tool, due to the use of routine data; (b) even though the
sample was large, subgrouping according to the BZD type
resulted in relatively small subgroups. Thus, we could infer a
pattern of use only for the more largely used BZDs.
However, in spite of the small subgroups, the presence of
statistically significant results underlines the strength of the
results.
On the basis of the present findings, some recommenda-
tions could be argued both in research and in clinical
practice. From the research point of view, studies evaluating
factors identifying subjects at risk to become long-term BZD
users and replication studies are warranted. In addition,
studies evaluating hypnotic and anxiolytic BZDs separately,
and, when possible, each BZD per se, are needed. From a
clinical point of view, BZDs should be prescribed on the
basis of their pharmacokinetic and pharmacodynamic
profiles, not being all the same [14]. In addition, cognitive
behavioral therapy [3] should be considered as alternative
treatment for those at risk of becoming long-term users.
Finally, pros and cons of BZDs recommendation should be
balanced under the light of behavioral toxicity and iatrogenic
comorbidity [42–48]. Indeed, a drug within its dose range
may produce alterations in mood, perceptual, cognitive,
and psychomotor functions that can limit the capacity of
the individual or constitute a hazard to his/her well-being(i.e., behavioral toxicity) [42–44,46]; in addition, a drug
treatment can modify the course, characteristics, and
responsiveness of the illness for which it was administered
(i.e., iatrogenic comorbidity) [45–48].
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